SCHEMBL39790

SCHEMBL39790

CCc1c(C(=O)O)ccc(O)c1O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SELL P14151 1/20 0.57
SELP P16109 1/20 0.57
CSNK2A1 P68400 1/20 0.42
MEN1 O00255 1/20 0.41
PDE4A P27815 1/20 0.41
BLVRB P30043 1/20 0.41
KDR P35968 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
KLKB1 P03952 1/20 0.41
CTSB P07858 1/20 0.41
MMP9 P14780 1/20 0.41
DNMT1 P26358 1/20 0.41
DNMT3B Q9UBC3 1/20 0.41
DNMT3L Q9UJW3 1/20 0.41
DNMT3A Q9Y6K1 1/20 0.41
CA12 O43570 3/20 0.41
CA1 P00915 3/20 0.41
CA2 P00918 3/20 0.41
CA7 P43166 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8374984 0.88 SELL (0.50) SELLSELPCA12CA1CA2
SCHEMBL31668786 0.86 SELL (0.48) SELLSELPCSNK2A1MEN1KDR
SCHEMBL542401 0.86 SELL (0.48) SELLSELPCSNK2A1MEN1KDR
SCHEMBL40220 0.85 SELL (0.53) SELLSELPCSNK2A1KAT8MCL1
SCHEMBL15255722 0.84 HSD17B1 (0.43) SELLSELPMEN1HTTKMT2A
SCHEMBL31336021 0.84 SELL (0.57) SELLSELPCSNK2A1MEN1PDE4A
SCHEMBL9874859 0.84 SELL (0.57) SELLSELPCSNK2A1MEN1PDE4A
SCHEMBL294836 0.83 CYP1A2 (0.50) SELLSELPMEN1KMT2ACA12
SCHEMBL18419577 0.82 SELL (0.45) SELLSELPCSNK2A1MEN1KDR
SCHEMBL8029592 0.82 ALDH1A1 (0.50) SELLSELPCSNK2A1KMT2ACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2900236-B1 TREATMENT OF WOLFRAM SYNDROME-RELATED NEURODEGENERATION UNIV BIRMINGHAM (GB) 2019-01-16 EP claimed
EP-1676591-B1 Compositions and methods to create a vascularized environment for cellular transplantation LIFESCAN INC (US) 2018-08-01 EP claimed
US-20130267594-A1 PROLYL HYDROXYLASE INHIBITORS AS RADIATION MITIGATORS AND RADIATION PROTECTORS DANA-FARBER CANCER INSTITUTE INC. (US) 2013-10-10 US claimed
WO-2012037212-A1 PROLYL HYDROXYLASE INHIBITORS AS RADIATION MITIGATORS AND RADIATION PROTECTORS DANA-FARBER CANCER INSTITUTE, INC. (US) 2012-03-22 WO claimed
US-20070122448-A1 Compositions and methods to create a vascularized environment for cellular transplantation REZANIA ALIREZA 2007-05-31 US claimed
EP-1676591-A2 Compositions and methods to create a vascularized environment for cellular transplantation LIFESCAN, INC. (US) 2006-07-05 EP claimed
EP-1006403-B1 Use of direct thermal transparent imaging materials including an organic silver salt for producing labels AGFA GEVAERT (BE) 2004-10-20 EP claimed
EP-1006405-B1 Black and white thermographic recording material with improved image tone AGFA GEVAERT (BE) 2003-07-23 EP claimed
US-20260102484-A1 ADJUVANTS FOR ENHANCING THE IMMUNE RESPONSE LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) 2026-04-16 US disclosed
CN-121795492-A Post-harvest fruit preservative fresh-keeping composite bacteriostatic agent and preparation method and application thereof 昆明理工大学 2026-04-07 CN disclosed
EP-4599856-A1 SCAR REDUCING WOUND CLOSURE MATERIALS Lankenau Institute for Medical Research (US) 2025-08-13 EP disclosed
EP-4587049-A1 ADJUVANTS FOR ENHANCING THE IMMUNE RESPONSE Lankenau Institute for Medical Research (US) 2025-07-23 EP disclosed
CN-119968127-A Animal food compositions with improved palatability and customizable properties and methods of making the same 玛氏公司 2025-05-09 CN disclosed
CN-119386094-A Method for optimizing shinyleaf yellowhorn tea extraction process 内蒙古民族大学 2025-02-07 CN disclosed
US-5589317-A Thermal transfer imaging process AGFA-GEVAERT N.V. (BE) 1996-12-31 US disclosed
EP-0671283-A1 Thermal transfer imaging process AGFA-GEVAERT N.V. (BE) 1995-09-13 EP disclosed
US-5084593-A Cyanine, aniline dyes for heat sensitive recording elements RICOH COMPANY, LTD. (JP) 1992-01-28 US disclosed
US-5008238-A Thermosensitive material with phenolic developer RICOH COMPANY, LTD. (JP) 1991-04-16 US disclosed
WO-1988002047-A1 METHOD AND PRODUCTS FOR SIZING PAPER AND SIMILAR MATERIALS WEYERHAEUSER COMPANY (US) 1988-03-24 WO disclosed
US-4188390-A Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines PFIZER INC. (US) 1980-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260102484-A1 ADJUVANTS FOR ENHANCING THE IMMUNE RESPONSE HIF1A, HIF1AN, EGLN3 SELL 3013/4885SELP 1790/4885CSNK2A1 848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.